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1. INTRODUCTION 
The myosin light chain kinases (MLCK) possess an 
absolute requirement for the binding of the calcium- 
bound form of calmodulin (CaM) for expression of 
catalytic activity (reviewed in [ 11). The discovery of the 
lodation and primary structure df the CaM-binding do- 
main df rabbit skeletal muscle MLCK (skMLCK) [2,3] 
sparked intense efforts to elucidate’ the mechanism by 
which it and pther enzyme! are activated by Ca,& 
Much of this effort has focused on the possibility,‘flrsi 
suggested by Kemp and coworkers [4], that the region 
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immediately adjacent o or overlapping with the CaM- 
binding domain might serve as an endogenous 
pseudosubstrate or autoinhibitor of catalysis by binding 
to the protein/peptide substrate binding pocket within 
the active site of the enzyme. The binding of CaM 
would remove the auoinhibitor from the active site 
allowing catalysis to proceed (reviewed in 5-71). The 
principal evidence for autoinhibition sprang from the 
observation that peptides modelled after the CaM- 
binding Gomains of +cken gizzard MLCK and 
skMLCK acted as comp&tjve, CaM-mediated in- 
hibitors of, catalysis with i&pe? ;o protein or peptide 
substrates [4,8]. With skMLC:K it was also observed 
that the binding model pep’tides to the active site 
counteracted the effects of C+M binding upon the ther- 
mal stability properties of the enzyme [9]! Zot aqd Puett 
[lo] reported that the complex produced by the covalent 
crosslinking of CaM to skMLCK retained significant 
catalytic activity in the absence of Ca2’, indicating that 
attachment of CaM at the proper location was suffi- 
cient to partially turn on catalysis. Shoemaker et al, [i I] 
demonstrated that inversion of the sequence of the 
CaM-binding domain of a nonmuscle MLCK, which 
leaves the adjacent putative autoinhibitory domain un- 
disturbed, produced a fully functional, Cal%regulated 
enzyme. 
Recerfl:, it hi hpen proposed that the behavior of 
skMLCK and several other CaM-regulated models 
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(skMLCK) and its calmodulin complex in a site-specific manner. Reaction was dependent upon the Presence of the adenosine moiety of FSBA, 
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and 0.40 mM, respectively. It is concluded that the MgATP-binding site on skMLCK remains accessible atall times and maintains a near constant 
conformation. 
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could be explained by a ‘flip-flop model’ in which 
MLCK possess a CaM-like domain to which the CaM- 
binding domain associates in the absence of CaM [12]. 
This binding event is thought to induce a conforma- 
tional shift affecting the active site that renders it 
catalytically non-functional. CaM-binding would ac- 
tivate the enzyme by disrupting the association of the 
CaM-binding domain with the internal CaM-like do- 
main and allowing the active site to relax into its 
catalytically-competent conformation. 
The evidence for both autoinhibitor and conforma- 
tional-shift models remains inferential in nature. In 
order to gain further insight into the events that take 
place when CaM binds to and activates rabbit skMLCK 
- especially those affecting catalysis, we have probed 
the MgATP substrate binding site of the enzyme using 
the ATP-like affinity labelling reagent 5 ’ -,%fluorosul- 
fonylbenzoyl adenosine (FSBA) [ 131, Specifically, we 
wished to determine (i) whether the MgATP binding 
site that must be present when the enzyme is activated 
by CaM remains accessible and recognizable in the 
absence of CaM, and (ii) whether this site undergoes a
conformational or other change of sufficient magnitude 
upon CaM binding so as to alter its affinity for or reac- 
tivity with FSBA. Portions of this work have been 
reported previously in preliminary form [ 141. 
2. MATERIALS AND METHODS 
2. I . Malerials 
Purchased materials included DMF (Fisher Scientific, Pittsburg, 
PA); HEPES (Research Organ& Inc., Cleveland, OH); FSBA 
(Sigma Chemical Co., St. Louis, MO); p-fluorosulfonyl benzoic acid 
(Aldrich Chemical Co., Milwaukee, WI); and [adenine-8-‘4C]FSBA 
(New England Nuclear). Peptides were synthesized by the chemical 
synthesis facility of the Howard Hughes Medical Institute in Seattle, 
Washington and purified and analyzed as previously described [8]. 
All other materials were obtained from previously listed sources [8,9]. 
2.2. Enzymes and other profeins 
skMLCK was purified from the back and hind limb skeletal muscle 
tissue of New Zealand white rabbits [IS]. CaM was purified from 
bovine testes [16]. skMLCK concentration was determined by the 
method of Bradford [17] using bovine serum albumin as standard and 
a molecular mass of 65 000 Da [18] to calculate molarity. CaM was 
estimated from its UV absorbance at 277 nm [19]. 
2.3. Reaction conditions for affinity IabeNing 
The reaction between skMLCK and FSBA was carried out at 25°C 
in a volume of 6Opl of 50 mM HEPES buffer, pH 7.5, containing 10 
mM M&12,0.5 mM CaClz, 0.2 M NaCI, 5% (v/v) DMF, and the con- 
centrations of FSBA indicated in the individual figure legends. The 
concentration of skMLCK was 0.1 mg/mI (1.5 pM). For reactions in- 
volving the skMLCKCaM complex, 5 ,&I CaM was also included. 
Mg”+ and NaCl were included in order to stabilize theskMLCK,CaM 
complex [9]. FSBA was added as a freshly made 20-fold concentrated 
stock solution in DMF. FSBA concentrations were determined by 
measuring the UV absorbance at 259 nm using an extinction coeffi- 
cient of 15800 M-‘-cm- [13]. Reaction was initiated by adding 
FSBA in DMF and mixing vigorously. At timed intervals the reaction 
was stopped by removing 4 /cl aliquots of the reaction mixture and 
diluting them 500-fold into IO mM MOPS, pH 7.0, containing 1 mM 
DTT, 0.2 mM EGTA, 0.1 M NaCI, 0.5 m&ml BSA, and 0.1% Triton 
X-100. The proportion of skMLCK molecules undergoing irreversible 
modification by FSBA was determined by measuring the MLCK ac- 
tivity remaining [8] using a peptide substrate (KKRAARATSNVFA; 
[20]). All results were corrected with mixtures containing DMF 
without FSBA. Experiments with p-fluorosulfonyl benzoic acid (FSB) 
utilized identical procedures, with the exception that the FSB was 
quantitated by weight. 
2.4. Stoichiometry of FSBA incorporation into skMLCK 
The stoichiometry of incorporation of covalently bound FSBA into 
skMLCK was determined as described by Colburn et al. [14] using 
[adenine-8-“CJFSBA. 
3. RESULTS AND DISCUSSION 
FSBA binds to and reacts with both skMLCK and its 
CaM complex, rendering the enzyme catalytically inac- 
tive through the covalent modification of the enzyme’s 
MgATP binding site. This conclusion is based on 
several criteria. First, inactivation required the presence 
of the adenosine moiety of FSBA (Fig. 1). FSB, which 
contains the reactive fluorosulfonyl group of FSBA but 
lacks the adenosine targeting moiety, produced little or 
TIME (mln) TIME (mln) 
Fig. I. Inactivation of skMLCK or skMLCK-C&l by FSBA. $kMLCK (top) or skMLCK#CaM [bottom] war incubated in the presence of no inac- 
tivating agent (a), 0.6 mM HSB (o), or 0.6 tnM FSBA (A) and nliquots of the reaction mixture removed and assayed for activity a! the indicated 
times as dexcribed in Materials and Methods, Shown in the in of the fraction of initial cntymc activity rcmaininp [h&?/f%)) versus time of 
incubation, 
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Fig. 2. Dependence of rate of inactivation on FSBA concentration. 
skMLCK (0) or skMLCK*CaM (e) was incubated with the indicated 
concentrations of FSBA under standard conditions as described in 
Materials and Methods. Shown plotted is the apparent first-order ate 
constant for inactivation, kapp, as a function of FSBA concentration. 
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Fig. 3. Inhibition of FSBA inactivation by MgATP. skMLCK [top] 
or skMLCK*CaM [bottom] was incubated with 0.6 or 0.4 mM FSBA, 
rcspcctively, under standard conditions with the following modifica- 
lions. Included in each reaction mixture were either no additional 
compounds (O), 10 mM MgATP (e), IO mM MgGTP (A) or 0.2 
mM substrate peptidc - KKRAARATSNVFA (A), The open circles 
(0) represent tile average of control values obtained for reaction 
InixNN% cofrtelning each of the above-listed compounds, but no 
BSf3h. Avert&r values were presented for the sake of clarity. 
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Fig. 4. Stoichiometry of [‘4C]FSBA incorporation into skMLCK. 
Samples of skMLCK were incubated with [adenine-8-‘4C]FSBA, 0.8 
mM, for varying periods of time, then analyzed for remaining enzyme 
activity and incorporation of [‘4C]radioactivity as described in 
Materials and Methods. Shown plotted is the proportion of enzyme 
activity remaining versus the mol of [“C]FSBA incorporated per mol 
of skMLCK. The line represents a least-squares fit of the data. 
no inactivation of either form of the enzyme (Fig. I). 
Second, the rate of reaction - as measured by the ap- 
parent first order rate constant kapP as related by the 
equation lx-@/E,) = - kapp x c where E is the quantity 
of activity measured at time t and &, is the amount of 
activity measured at t=O - saturated with increasing 
concentrations of FSBA (Fig. 2). Third, MgATP, but 
not MgGTP or a peptide substrate, inhibited the reac- 
tion (Fig. 3). Lastly, inactivation of skMLCK was ac- 
companied by the nearly stoichiometric incorporation, 
0.84 mol/mol, of covalently-bound 14C-labelled FSBA 
into skMLCK (Fig. 4). The kinetic parameters for each 
reaction were determined using a Hanes-Woolf plot 
10 
n 
“-0.0 -034 0.0 Om4 088 1.2 1.6 2.0 
FSSA (mM) 
Fig. 5. Analysis of the kinetic parameters for the FSBA inactivation 
of skMLCK or rkMLCK*CaM, Shown is a Hanes-Woolf plot [S/V 
versus .s] of the data in Fig, 2 describing the dependence of the rate 
of inactivation of skMLCK (0) or skMLCK.CaM (0) on the concerr- 
rrarian of FSUA The lines showli represent least-squarer fita Of the 
dotut 
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(FSBA/S,, = FSBA/k3 +Ki/k3 [al]) as shown in REFERENCES 
Fig. 4. The rate constant for the conversion of the 
reversible enzyme. FSBA complex to the covalent en- 
zyme-FSBA complex, k3, is essentially identical 
whether skMLCK or skMLCK-CaM is the target 
species (0.038 min-’ and 0.040 min-‘, respectively), 
The equilibrium dissociation constants of the non- 
covalent skMLCK * FSBA and skMLCK - CaM - FSBA 
complexes differed by about two-fold (RYi=O.40 mM 
and 0.18 mM, respectively), with skMLCK*CaM 
displaying the greater affinity. 
The reactivity of skMLCK and its CaM complex with 
FSBA indicates that the MgATP binding site on the en- 
zyme remains acsessible, and recognizable as such, even 
when the enzyme is in the catalytically inactive, CaM- 
free state. This behavior contrasts with that of the 
multifunctional CaM-dependent protein kinase type II, 
for which it has been proposed that activity is 
modulated through the blockage of the MgATP- 
binding site [22]. The shift in Ki, the dissociation cons- 
tant for FSBA, of some two-fold upon the transit of 
skMLCK between the CaM-bound and CaM-free states 
indicates that this site was subject to some degree of 
change, perhaps conformational in nature, during this 
process. However, the relatively small shift in Ki 
observed, coupled with the virtually unchanged value of 
k3, implies that the degree of alteration is relatively 
small. Such behavior is consistent with the basic tenets 
of autoinhibitor models for the regulation of skMLCK. 
The possibility still remains that another quite different 
mechanism might more accurately describe the process 
of CaM activation. However, any such model must ac- 
commodate the observed maintenance of the ac- 
cessibility and recognizability of the MgATP-binding 
site during the activation-inactivation cycle, 
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